Biotechnology BIS Awarded Contract Worth EUR 30 Million for a Biotechnology Plant
BIS Industrietechnik Salzburg, a subsidiary of the Bilfinger Berger Industrial Services Group, has been awarded a contract by US biotech company Genzyme for the mechanical installation of a production facility to produce the active agent in a treatment for Pompe Disease.
Geel, Belgium – The heart of the plant, which is to be built in Geel in Belgium, is formed by two production lines each comprising a 4,000 litre bioreactor for producing the therapeutic protein Myozyme. The plant is to be completed by the end of September 2012. The general architect for the plant is the PM Group, Ireland. The contract has a total volume of EUR 30 million.
BIS Industrietechnik Salzburg previously worked with this company on another large project in Paris last year. “Projects attracting a great deal of international attention such as the recent one in Paris and now also in Belgium confirm the reputation which the BIS Group has acquired in the biotechnology/pharmaceuticals segment,” explains Dr. Joachim Kreysing, Executive Vice President of the BIS Group.
Ludwig Paradeiser, General Manager of BIS Industrietechnik Salzburg, sees the contract as a crucial step in ongoing efforts to internationalise the company’s business activities: “Genzyme is one of the world’s leading biotechnology companies. We are very pleased that we were able to prevail over renowned peers. The project in Belgium will allow us to additionally extend our international activities.”